
Trending News
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
